COYA Coya Therapeutics, Inc.
Coya Therapeutics, Inc. (COYA) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.7% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Coya Therapeutics, Inc.
Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya Therapeutics Inc. is based in HOUSTON.
Sector
Healthcare
Industry
Biotechnology